Eurobio Scientific: CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER

07 Nov 2023
www.globenewswire.com
Executive Change
Eurobio Scientific: CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER
CATHERINE COURBOILLET TO JOIN EUROBIO SCIENTIFIC BOARD AS AN INDEPENDENT MEMBER
Paris, November 7, 2023, 5:40 pm
Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, today announces Ms Catherine Courboillet has agreed to join the Board of Directors. A resolution relating to her appointment will be included on the agenda of the next general shareholder meeting in June 2024.
Catherine Courboillet's appointment is part of the Board strategy to broaden the profiles and skills of its members in the field of medical diagnostics. She will bring her expertise in customer experience and her extensive knowledge of key market players.
Ms. Catherine Courboillet began her career at Pharmacia DIAG, a Swedish in vitro diagnostics company, where she quickly held several management positions including sales and marketing. She then developed the specialized biology laboratory of Générale de Santé before joining Cerba in 1999, which became the Cerba Healthcare Group under her leadership. She has 30 years of experience in the field of life sciences and medical diagnostics.
She has developed, over the years, unique skills in business management and has carried out numerous external growth projects in the field of medical diagnostics in France, Europe and internationally.
Denis Fortier, CEO of Eurobio Scientific, déclares : “I am very honored to welcome Catherine to the Group's Board of Directors and benefit from her strategic vision, her knowledge of the market and customers as well as her advice in order to continue our growth in France and internationally.“
Catherine Courboillet complements : “I have been convinced by the vision and energy of Denis and the teams. I am very pleased to support them in this new phase of their growth journey for the benefit of patients and healthcare stakeholders.“
Eurobio Scientific is a key player in the field of specialty in vitro diagnostics. It is involved from research to manufacturing and commercialization of diagnostic tests in the fields of transplantation, immunology and infectious diseases, and sells instruments and products for research laboratories, including biotechnology and pharmaceutical companies. Through many partnerships and a strong presence in hospitals, Eurobio Scientific has established its own distribution network and a portfolio of proprietary products in the molecular biology field. The Group has approximately 290 employees and four production units based in the Paris region, in Germany, in the Netherlands and in the United States, and several affiliates based in Dorking UK, Sissach Switzerland, Bünde Germany, Antwerp Belgium, Utrecht in The Netherlands and Milan in Italy.
Eurobio Scientific's reference shareholder is the EurobioNext holding company which brings together its two directors, Jean-Michel Carle and Denis Fortier, alongside the "Pépites et Territoires" by AXA & NextStage AM investment program, managed by NextStage AM.
For more information, please visit: www.eurobio-scientific.com
The company is publicly listed on the Euronext Growth market in Paris
Euronext Growth BPI Innovation, PEA-PME 150 and Next Biotech indices, Euronext European Rising Tech label.
Symbol: ALERS - ISIN Code: FR0013240934 - Reuters: ALERS.PA - Bloomberg: ALERS:FP
Contacts
Denis Fortier, Chairman and CEO
Olivier Bosc, Deputy CEO/ CFO
Tel. +33(0) 1 69 79 64 80Calyptus
Mathieu Calleux
Investors Relations
Tel. +33(1) 53 65 68 68 - eurobio-scientific@calyptus.net
Attachment
231107_PR_Eurobio Scientific_Nomin_CCourboillet_EN_


For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
-
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.